Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL)
Eugenio De Corso,Ernesto Pasquini,Matteo Trimarchi,Ignazio La Mantia,Fabio Pagella,Giancarlo Ottaviano,Massimiliano Garzaro,Carlotta Pipolo,Sara Torretta,Veronica Seccia,Elena Cantone,Andrea Ciofalo,Daniela Lucidi,Gian Luca Fadda,Pia Clara Pafundi,Stefano Settimi,Claudio Montuori,Francesca Anastasi,Giulio Pagliuca,Angelo Ghidini,Carlo Cavaliere,Marianna Maffei,Francesco Bussu,Stefania Gallo,Frank Rikki Mauritz Canevari,Gaetano Paludetti,Jacopo Galli,Dupireal Italian Study Group,Camilla Spanu,Davide Paolo Porru,Simone Lo Verde,Marco Corbò,Alessandro Cantiani,Daniela Furno,Giuseppe D'Agostino,Leandro Maria D'Auria,Gabriele De Maio,Giuseppe Alberto Di Bella,Daniele Penazzi,Dario Antonio Mele,Tiziana Di Cesare,Rampi Andrea,Tanzini Umberto,Tommaso Saccardo,Giuseppe Roccuzzo,Federica Cipolla,Martina Ragusa,Egle Grigaliute,Matteo Alicandri Ciufelli,Leonardo Roncadi,Davide Rizzo,Carla De Vita,Paolo Farneti,Gabriella Todero,Lodovica Cristofani-Mencacci,Erica Statuti,Giovanni Cavallo,Anastasia Urbanelli,Francesco Ferrella,Flavio Arnone,Claudio Di Nola,Lorenzo Pignataro,Nicolò Nava,Paolo Russo,Vincenzo Savastano,Simonetta Masieri,Valeria Dell'Era,Paolo Aluffi Valletti,Fabio Sovardi,Vera Siragusa,Veronica Clemenzi,Andrea Stolfa,Edi Simoni,Laura Astolfi
DOI: https://doi.org/10.1111/all.15772
IF: 12.4
Allergy
Abstract:Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduced health-related quality of life. Findings from clinical trials have demonstrated the effectiveness of dupilumab in CRSwNP, although real-world evidence is still limited. Methods: This Phase IV real-life, observational, multicenter study assessed the effectiveness and safety of dupilumab in patients with severe uncontrolled CRSwNP (n = 648) over the first year of treatment. We collected data at baseline and after 1, 3, 6, 9, and 12 months of follow-up. We focused on nasal polyps score (NPS), symptoms, and olfactory function. We stratified outcomes by comorbidities, previous surgery, and adherence to intranasal corticosteroids, and examined the success rates based on current guidelines, as well as potential predictors of response at each timepoint. Results: We observed a significant decrease in NPS from a median value of 6 (IQR 5-6) at baseline to 1.0 (IQR 0.0-2.0) at 12 months (p < .001), and a significant decrease in Sino-Nasal Outcomes Test-22 (SNOT-22) from a median score of 58 (IQR 49-70) at baseline to 11 (IQR 6-21; p < .001) at 12 months. Sniffin' Sticks scores showed a significant increase over 12 months (p < .001) compared to baseline. The results were unaffected by concomitant diseases, number of previous surgeries, and adherence to topical steroids, except for minor differences in rapidity of action. An excellent-moderate response was observed in 96.9% of patients at 12 months based on EPOS 2020 criteria. Conclusions: Our findings from this large-scale real-life study support the effectiveness of dupilumab as an add-on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.